solute carrier family 35 member B1Genealiases: AXER · UGTREL1
Q-omics provides the consensus-scored SLC35B1 profile across patient tissues and cancer cell-line models. SLC35B1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, SLC35B1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, SLC35B1 protein abundance shows 31,635 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, KIRC, and LUAD as cancer lineages where SLC35B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC35B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC35B1 survival associations across molecular data types. SLC35B1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC35B1 RNA expression–survival associations across cancer types. High SLC35B1 expression shows unfavorable associations in ACC, KICH, UVM, HNSC, BLCA and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for SLC35B1 RNA expression.
This table summarizes SLC35B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC35B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC35B1 shows lower tumor expression in THCA and higher tumor expression in KIRC, BLCA, KIRP, LIHC and LUAD. The KIRC box plot shows higher SLC35B1 RNA expression in tumor versus normal tissue (log2 FC = +0.856, t-test p < 0.001).
This table shows molecular features associated with SLC35B1 in patient tissues and cancer cell lines. In patient samples, SLC35B1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC35B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
